Hyperglycæmi eller forværring af eksisterende diabetes er rapporteret i meget sjældne tilfælde under behandling med RISPERDAL CONSTA.
The need for increased patient monitoring during the switch period was discussed and the CHMP considered that the data provided showed no worsening in clinical symptoms after the therapy with long-acting risperidone was initiated.